1. Product portfolio addressing large and growing markets

Focusing on becoming a leader in the large and growing space of mental illness and substance use disorders. In parallel, Orexo is addressing the ongoing opioid epidemic, one of the largest health cri­ses to take place in the US and a growing global concern.

2. Strong cash conversion to support growth

Lead product ZUBSOLV®, for the treatment of opioid use disorder, is a strong cash and profit contributor, enabling continued investment in on-market products, and R&D.

3. Leveraging our US commercial excellence

Strategic focus on leveraging its commercial excellence and strong market access network in the US, by adding more products to the US commercial platform.

4. Pipeline targeting unmet medical needs

Continue to build on the strong experience of developing products with worldwide approval by expanding the pipeline with multiple short-time to market assets based on innovative drug delivery and digital technologies, addressing unmet medical needs.

5. Entering digital therapeutics, a new evidence-based frontier in patient care

Digital therapeutics increase access to treatment and improve treatment outcomes, and is set to become an integral part of the global healthcare landscape. Mental illness and substance use disorders are areas where it is most needed.